Colonic Tissue Expression of Madcam-1 Is Not Predictive of Vedolizumab Responsiveness in Inflammatory Bowel Disease

Authors

• Nikhil Reddy, The University of Chicago Medicine
• Jeremy A. Klein, The University of Chicago Medicine
• Nikita Thomas, The University of Chicago Medicine
• Dejan Micic, Loyola University Medical Center
• Zifeng Deng, The University of Chicago Medicine
• David T. Rubin, The University of Chicago Medicine
• Russell D. Cohen, The University of Chicago Medicine
• Sushila Dalal, The University of Chicago Medicine
• Britt Christensen, University of Melbourne
• Haider I. Haider, New York Medical College
• Vesta Valuckaite, Bayer Corporation, USA
• Katherine R. Meckel, The University of Chicago
• Marc Bissonnette, The University of Chicago
• Christopher R. Weber, The University of Chicago Medicine
• Joel Pekow, The University of Chicago Medicine

DOI

10.1111/cts.70422

Journal Title

Clinical and Translational Science

Document Type

Article

Publication Date

12-1-2025

Department

Medicine

Keywords

immunology, inflammation, molecular therapeutics, monoclonal antibodies, pharmacology, therapeuticsgastrointestinal

Disciplines

Medicine and Health Sciences

Abstract

We assessed the predictive value of MAdCAM-1 expression on response to vedolizumab in patients with inflammatory bowel disease. This was a retrospective, single-center, cohort study including 109 patients with pretreatment inflammation who completed at least three doses of vedolizumab. We described clinical and endoscopic outcomes of patients based on MAdCAM-1 expression. There was no significant difference in MAdCAM-1 expression when stratified by histology. Patients in clinical remission at 14 weeks had significantly lower median baseline MAdCAM-1 expression (37425.3 vs. 46278.9, p < 0.015). There was no difference in pretreatment MAdCAM-1 expression among patients who later achieved endoscopic or biologic response. In the posttreatment cohort, lower MAdCAM-1 expression was associated with an increased likelihood of endoscopic or biologic response (36719.5 vs. 44229.9, p < 0.038). However, posttreatment MAdCAM-1 expression did not significantly differ when stratified for clinical remission at 14 weeks. Ultimately, MAdCAM-1 immunohistochemistry has limited utility as a predictive biomarker but may provide insights into vedolizumab-associated bowel healing.

Recommended Citation

Reddy, N., Klein, J., Thomas, N., Micic, D., Deng, Z., Rubin, D., Cohen, R., Dalal, S., Christensen, B., Haider, H., Valuckaite, V., Meckel, K., Bissonnette, M., Weber, C., & Pekow, J. (2025). Colonic Tissue Expression of Madcam-1 Is Not Predictive of Vedolizumab Responsiveness in Inflammatory Bowel Disease. Clinical and Translational Science, 18 (12). https://doi.org/10.1111/cts.70422